

The logo features the text 'Rx+' in a bold, sans-serif font. The 'R' is red, the 'x' is grey, and the '+' is grey. The text is enclosed within a grey circular graphic that is partially open at the top and bottom.

Rx+ BUSINESS ACCELERATOR

Improving Outcomes that Patients Care About



DISCLAIMER

In this material, statements made with respect to current plans, estimates, strategies and beliefs and other statements that are not historical facts are forward-looking statements about the future performance of Astellas Pharma. These statements are based on management's current assumptions and beliefs in light of the information currently available to it and involve known and unknown risks and uncertainties. A number of factors could cause actual results to differ materially from those discussed in the forward-looking statements. Such factors include, but are not limited to: (i) changes in general economic conditions and in laws and regulations, relating to pharmaceutical markets, (ii) currency exchange rate fluctuations, (iii) delays in new product launches, (iv) the inability of Astellas to market existing and new products effectively, (v) the inability of Astellas to continue to effectively research and develop products accepted by customers in highly competitive markets, and (vi) infringements of Astellas' intellectual property rights by third parties.

This presentation also includes information about investigational Astellas products that have not been approved by regulatory agencies. Information about potential future uses is intended only for discussion of an investigational product's regulatory lifecycle development and should not be interpreted as an intent to promote unapproved uses. The contents of this presentation should not be used in any manner to directly or indirectly promote or sell the investigational product for unapproved uses. Astellas prohibits the promotion of unapproved uses and complies with all applicable laws, regulations and company policies.

CORPORATE DATA

HQ | *Founded in 1923 (launched as Astellas Pharma Inc. in 2005), headquartered in Nihonbashihoncho, Chuo City, Tokyo*


Leadership | *Naoki Okamura, President & CEO*

Mission | *On the forefront of healthcare change to turn innovative science into proven value for patients.*

Focus Areas | *Immuno-oncology, genetic regulation, mitochondria, blindness & regeneration and targeted protein degradation*

Global Sales† | *Revenue: \$9.76B, Sales: \$1.84B. 19% of revenue reinvested in R&D*

Employees† | *14,522 (top 25 global pharma companies)*



† As of March 31st, 2022 (end of FY21)

WHAT IS Rx+ BUSINESS ACCELERATOR?



A Vision

A world where people can live mentally and physically healthy lives and be true to themselves through healthcare solutions based on scientific evidence

Beyond Astellas' Core

- ➔ *Distinct Therapeutic Areas*
- ➔ *Novel Modalities*
- ➔ *Non-Pharma Technologies*

Here To Stay

- ✓ *Focused strategy utilizing key resources*
- ✓ *Guided by Astellas' principles of patients first*
- ✓ *Leverage global reach and capabilities*

OPPORTUNISTIC TRENDS



Increasing Use of Remote Medicine

*COVID Pandemic enabled remote medicine as a viable treatment pathway
Treating the patient in their own home has also resulted in improved outcomes
Technological & data analytical advances have also enabled remote medicine*

Higher Demands on HCPs' Time

*Administrative burden is stretching physicians and taking time away from their value-adding activities
Healthcare providers are aware of the lack of efficiency
Businesses that reduce this burden will be “pushing against an open door”*

Growing Healthcare Cost Base

Healthcare expenditure continues to increase globally

Aging Population

These patients are less able to visit the hospital for treatment and are one of the main contributors to increasing healthcare costs




CREATING VALUE



Chronic Diseases of Aging Oncology, Cardiology, Stroke

High unmet need, growing problem, home care potential, stress on healthcare system




End-to-End Adaptive Technologies Sense, Analyze, Intervene

Combined devices/ software, & digital therapies, improved outcomes, increased convenience, reduced costs, clinical evidence needed

Business Type B2B, B2B2C, Global

Clinical evidence required, reimbursement possible, interconnection opportunity, challenging for start-ups to sell to hospitals


INNOVATION APPROACH



SUCCESS STORIES




A Ac Ct



Astellas is developing ASP5354 as an imaging agent for intraoperative ureter visualization during minimally invasive and open abdominopelvic surgeries, that might help prevent ureteral injury.


P Cd Ct



“Welldoc is excited to collaborate with Astellas as part of our evolution as a digital health company with a commitment to help improve the health of those living with chronic disease”

- Kevin McRaith, President and CEO, Welldoc

A Cd Ac Ct



“I believe that Iota’s technology that can be applied not only to the current programs we are working on, but to broader types of diseases that have yet to be worked on.”

- Kenji Yasukawa, former Astellas CEO

P Cd



MYHOLTER II from M. Heart is a system that analyzes Holter ECG data efficiently with high accuracy using unique artificial intelligence.



PARTNERSHIP



Rx+ Business Accelerator actively seeks to partner

with visionaries and innovators to create ground-breaking technologies in digital health with our community of like-minded entrepreneurs to create VALUE for patients.

Michael Rennaker, Director of External Innovation
Michael.Rennaker@astellas.com